Elizabeth Dieckmann
Psychiatric/Mental Health · Indianapolis, INNPI 1336927300
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,924, more than ten times the $162 reported in 2023.
Across 233 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$596
- AbbVie$470
- Vanda Pharmaceuticals Inc.$437
- Otsuka America Pharmaceutical, Inc.$386
- Neurocrine Biosciences, Inc.$297
- Corium, LLC$243
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,40996%
- Education$1244%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,533 in reported general payments places this provider in the 85th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 42 | $60,102 |
| RexultiBrexpiprazole | 24 | $34,514 |
| TrintellixVortioxetine Hydrobromide | 24 | $23,457 |
| AristadaAripiprazole Lauroxil | 11 | $18,900 |
| Lurasidone Hcl | 21 | $4,969 |
| Aripiprazole | 71 | $3,625 |
| Hydroxyzine Hcl | 116 | $3,055 |
| Duloxetine Hcl | 102 | $3,022 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $2,051 |
| Vilazodone Hcl | 18 | $1,972 |
| Buspirone Hcl | 82 | $1,964 |
| Trazodone Hcl | 106 | $1,696 |
| Bupropion XlBupropion Hcl | 64 | $1,556 |
| Lamotrigine | 101 | $1,555 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 70 | $1,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $470 | $60,10242 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $386 | $34,51424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $48 | $23,45724 claims |
| Alkermes, Inc.Aristada | $236 | $18,90011 claims |
| Almatica Pharma LLCSertraline Hcl | $47 | $80287 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Indianapolis
- Sonya RuedlingerIndianapolis$134K
- Devan GravesIndianapolis$12K
- Clyde YanIndianapolis$9K
- Beth DelamboIndianapolis$7K
- Olga Marie JiodioIndianapolis$6K
- Lindsay RussellIndianapolis$5K
- Nina VoigtIndianapolis$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.